Published in final edited form as:

Org Lett. 2012 April 6; 14(7): 1869–1871. doi:10.1021/ol300466a.

Enantioselective Total Synthesis of (+)-Amabiline

Timothy J. Senter, Olugbeminiyi O. Fadeyi, and Craig W. Lindsley*

Departments of Chemistry and Pharmacology, Vanderbilt University, Nashville, Tennessee 37232.

Abstract

The first total synthesis of (+)-amabiline, an unsaturated pyrrolizidine alkaloid from *Cynoglossum amabile* is reported. This convergent, enantioselective synthesis proceeds in 15 steps, 10 steps longest linear sequence, in 6.2% overall yield and features novel methodology to construct the unsaturated pyrrolizidine or (–)-supinidine core.

Pyrrolizidine alkaloids (**1**), historically referred to as necine bases, share a common azabicyclo[3.3.0]octane core, but differ based on the oxygenation pattern and whether or not C1–C2 is saturated (Figure 1).¹ While the amine bases themselves are rarely isolated in nature, the corresponding mono- and di-esters are more common, as either the tertiary amine or the *N*-oxide, **2–5**.¹ Members of this family of alkaloids possess a wide range of biological activities including antitumor, antibacterial, anti-inflammatory, carcinogenic and hepatotoxic activity, with several members entering human clinical trials.^{1–5} Plants containing pyrrolizidine alkaloids are toxic to humans and animals, but several insect species have evolved to employ them for their own chemical defense.⁶ Interestingly, the toxicity has been attributed to liver metabolism of the C1–C2 unsaturated congeners leading to the generation of highly reactive alkylating agents.⁷

A number of racemic routes to the pyrrolizidine alkaloid core (**1**) have been developed, but recent efforts have focused on asymmetric approaches.^{1–5} The majority of these approaches rely on the chiral pool, employing L-proline, malic acid or carbohydrates as chiral starting materials.¹ Based on the synthetic challenge, the diverse biological activity and our recently reported methodology to construct multiple bicyclic azacine systems,⁸ we decided to apply our methodology towards the enantioselective synthesis of (+)-amabiline (**3**), an unsaturated pyrrolizidine alkaloid, isolated in 1967 from *Cynoglossum amabile*, that has yet to be the subject of a total synthesis.^{7,9–12}

Our retrosynthesis first cleaved the ester bond to liberate the necine base (–)-supinidine (**6**) and (–)-viridifloric acid (**7**). **6** has been synthesized previously, but the most expedient route required 18 steps.¹³ By employing a novel extension of our newly developed azacine methodology,⁸ **6** would be accessed from **8**, which would be derived from commercial diol **10** and (*S*)-*tert*-butyl sulfinimine **11**. (–)-Viridifloric acid (**7**) would be prepared as prescribed by Schulz,¹⁴ via **9**, from commercial **12** and **13**.

craig.lindsley@vanderbilt.edu.

Supporting Information Available: Experimental procedures, characterization data, and ¹H and ¹³C NMR spectra for all new compounds. This material is available free of charge via the internet at <http://pubs.acs.org>.

Efforts initially focused on the synthesis of **7** (Scheme 2).¹⁴ Alkylation of phosphonate ester **12** with **13** provided **14** in 93% yield. A Horner-Wadsworth-Emmons reaction with acetaldehyde provided alkene **15**, which then underwent a Sharpless dihydroxylation to afford (*S,S*)-diol **16** in >8:1 *dr*. Ester hydrolysis gave the (–)-viridifloric acid (**7**), identical in all respects to the natural acid, which was then protected as the dioxolane congener **9**. Thus, the synthesis of **9** required five steps and proceeded in 48% overall yield.

With **7** in hand, attention was now directed to the synthesis of key intermediate **8** (Scheme 3). Commercial diol **10** was mono-silylated. MnO₂ oxidation of the allylic alcohol then delivered aldehyde **17** in 84% yield for the two steps. Condensation of **17** with (*S*)-*tert*-butyl sulfinimine **11** gave **18** in 79% yield.^{8,15–17} Addition of Grignard reagent **19** provides **20** in >9:1 *dr*,^{8,15–21} which is subsequently allylated to deliver **21** in 77% yield for the two steps. A ring closing metathesis reaction employing Grubbs II²² smoothly led to pyrrolidine **22**, and a TBAF deprotection generated the key intermediate **8**. Single X-ray crystallography (Figure 2) confirmed the absolute stereochemistry of **8** as (*S,S*).²³ Here, we anticipated that deprotection of the acetal and the sulfinamine would liberate the free aldehyde and amine, respectively, followed by an intramolecular condensation to form the imine that would then be reduced *in situ* to provide (–)-supinidine (**6**). However, classical Ellman conditions and a number of other variants failed to facilitate this transformation, affording complex mixtures of polar species.

Therefore, we elected to first couple **8** and **9**, followed by global deprotection and intramolecular reductive amination. However, this too proved difficult, due to the sterically hindered acid **9**. We evaluated several coupling reagents (EDCI/DMAP, TBTU/DBU, DCC/DMAP, HATU/DIEA) and protocols, but none provided any trace of the ester product. Therefore, we decided to convert the hydroxyl of **8** into a leaving group, and attempt to install the ester linkage by employing the acid as a nucleophile. A mesylate derivative afforded a 45% conversion to the desired ester, but **23**, a tosylate variant, afforded the desired ester in 82% yield (Scheme 4). A final acid-mediated global deprotection of the acetal, the dioxolane and the sulfinamine enabled the intramolecular condensation to form the imine, which was then reduced *in situ* by MP-BH(OAc)₃ to deliver amabiline (**3**) in 37% yield in a five step, one-pot reaction cascade (an average of 82% yield/transformation). Thus, the first total synthesis of (+)-amabiline (**3**) was completed in 15 synthetic steps (10 steps longest linear sequence) and in 6.2% overall yield. Our synthetic amabiline was identical in all respects to the data reported for natural **3**. Moreover, this represents a notable improvement, as previous efforts have required up to 18 steps to deliver (–)-supinidine (**6**), the parent necine base.¹³

Based on the structural similarity of **3** to other pyrrolizidine alkaloids with anticholinergic activity,^{1–5} we evaluated our synthetic **3** against all five human mAChR receptors (hM₁–M₅). Interestingly, **3** possessed no activity at any of the mAChRs (IC₅₀s >10 μM), as well as a larger collection of GPCRs, ion channels and transporters.

In summary, we have completed the first total synthesis of (+)-amabiline (**3**), requiring only 15 synthetic steps (10 steps longest linear sequence) in 6.2% overall yield. This highly convergent and concise synthesis will enable the preparation of unnatural, unsaturated pyrrolizidine alkaloids for additional biological evaluation. Further refinements are in progress and will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported, in part, by the Department of Pharmacology and Vanderbilt University. Funding for the NMR instrumentation was provided in part by a grant from NIH (S10 RR019022).

References

1. For reviews on the pyrrolizidine alkaloids see: Robins DJ. J. Nat. Prod. Report. 1989; 6:221. Ikeda M, Sato T, Ishibashi H. Heterocycles. 1988; 27:1465. Dai W-M, Nagao Y. Heterocycles. 1990; 30:1231–1261.
2. Culvenor CCJ, Dowling DT, Edgar JA, Jago MV. Ann. NY Acad. Sci. 1969; 163:837.
3. Zalkow LH, Glinski JA, Gelbaum LT, Fleischmann TJ, McGowan LS, Gordon MM. J. Med. Chem. 1985; 28:687. [PubMed: 4009589]
4. Suffness, M.; Cordell, GA. The Alkaloids: Chemistry and Pharmacology. Brossi, A., editor. Vol. Vol. 25. NY: Academic Press; 1985.
5. Cheeke, PR. Toxicants of Plant Origins. Cheeke, PR., editor. Vol. Vol. 1. Florida: CRC Press; 1989.
6. Hartmann T, Biller A, Witte L, Ernst L, Boppre M. Biochem. Syst. Ecol. 1990; 18:549–556.
7. White L, Rubiolo P, Bicchi C, Hartmann T. Phytochemistry. 1993; 32:187–196.
8. Faedyi OO, Senter TJ, Hahn KN, Lindsley CW. Eur. J. Chem.
9. Culvenor CCJ, Smith LW. Aust. J. Chem. 1967; 20:2499–2503.
10. El-Shazy A, Sarg T, Ateya A, Aziz EA, Witte L, Wink M. Biochem. Syst. Ecol. 1996; 24:415–421.
11. Roeder E, Breitmaier E, Birecka H, Frohlich MW, Badzies-Crombach A. Phytochemistry. 1991; 30:1703–1706.
12. In 1993, a structurally unrelated *Amaryllidaceae* alkaloid, was isolated and also named amabiline. However, the moniker of amabiline has been applied to **3** in multiple manuscripts over the past 45 years. For the isolation and synthesis of the *Amaryllidaceae* alkaloid also named amabiline see: Likhitwitayawuid K, Angerhofer CK, Pezzuto JM, Cordell GA, Ruangrunsi N. J. Nat. Prod. 1993; 56:1331. [PubMed: 8229016] Findlay AD, Banwell MG. Org. Lett. 2009; 11:3160–3162. [PubMed: 19586069]
13. Takahata, Banba Y, Momose T. Tetrahedron. 1991; 47:7635–7644.
14. Stritzke K, Schulz S, Nishida R. Eur. J. Chem. 2002:3884–3892.
15. Brinner KM, Ellman JA. Org. Biomol. Chem. 2005; 3:2109–2113. [PubMed: 15917897]
16. Schulte ML, Lindsley CW. Org. Lett. 2011; 13:5684–5687. [PubMed: 21942742]
17. Liu G, Cogan DA, Owens TD, Tang TP, Ellman TP. J. Org. Chem. 1999; 64:1278–1284.
18. Tang TP, Ellman JA. J. Org. Chem. 2002; 67:7819–7832. [PubMed: 12398509]
19. Weix DJ, Shi Y, Ellman JA. J. Am. Chem. Soc. 2005; 127:1092–1093. [PubMed: 15669835]
20. Brak K, Ellman JA. J. Am. Chem. Soc. 2009; 131:3850–3851. [PubMed: 19256498]
21. Cogan DA, Liu G, Ellman JA. Tetrahedron. 1999; 55:8883–8904.
22. Kuhn KM, Champagne TM, Hong SH, Wei W-H, Nickel A, Lee CW, Virgil SC, Grubbs RH, Pederson RL. Org. Lett. 2010; 125:984–987. [PubMed: 20141172]
23. See the Supporting Information for full details.

2, 9-angeloylplatynecine

4, indicine *N*-oxide

3, (+)-amabiline

5, monocrotaline

Figure 1.
Structures and numbering convention of pyrrolizidine alkaloids **1**, and representative examples **2–4**.

Figure 2.
X-ray structure (ORTEP) of key intermediate **8**, confirming the correct (*S,S*)-stereochemistry.

Scheme 1.
Retrosynthetic analysis of (+)-amabiline (**3**).

Scheme 2.
Synthesis of protected (-)-viridifloric acid (**9**).

Scheme 3.
Synthesis of key intermediate **8** and attempted synthesis of **6**.

Scheme 4.
Synthesis of (+)-amabiline (**3**).